NapaJen

Unlocking Potential of Oligonucleotide DrugsNapaJen’s proprietary technology includes the world’s only oligonucleotide drug delivery platform capable of targeting Dectin-1 positive immune cells such as dendritic cells and macrophages. NapaJen Pharma is a clinical-stage, biopharmaceutical company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel therapeutics. NapaJen Pharma has developed a novel solution designed to overcome these delivery challenges. NapaJen Pharma’s oligonucleotide delivery platform provides broad opportunities to companies seeking solutionsfor development of oligonucleotide therapeutics. Transforming Patient Care with Next-Generation Oligonucleotide TherapeuticsNapaJen Pharma is a clinical-stage biopharmaceutical company developing a new level of oligonucleotide drugs that for the first time can be delivered to target immune cells, overcoming a critical delivery challenge that has limited the development of nucleic acid-based therapeutics to date. Applying Proprietary Approach: Internal Pipeline and PartneringNapaJen Pharma has built a pipeline of internal drug candidates that includes NJA-730, its lead program in clinical development for prevention of acute immune diseases associated with bone marrow transplants, as well as preclinical programs in the area of immuno-oncology and vaccine adjuvants. In addition to its internal programs, the company is also leveraging its breakthrough delivery technology to position itself as a partner-of-choice for biotechnology and pharmaceutical companies seeking to develop their own novel oligonucleotide therapeutics. While nucleic acid-based drugs have demonstrated significant therapeutic potential, their efficient and targeted delivery has presented key challenges to drug developers.